Moving to better COPD care—changes to and challenges for GOLD.
noviembre 12, 2026
COPD care and GOLD 2026: disease activity, exacerbation risk, treatment escalation and multimorbidity in a more proactive approach.
COPD care and GOLD 2026: disease activity, exacerbation risk, treatment escalation and multimorbidity in a more proactive approach.
Blood biomarkers including CC16, sRAGE and SPD identify pre-COPD lung function trajectories and may improve early COPD risk detection and prevention.
Sleep apnea is highly prevalent in Long-COVID patients. Sleep studies may help identify treatable causes of persistent symptoms and insomnia.
Analysis of COPD management in primary care highlighting the role and underutilisation of nursing consultations and healthcare utilisation patterns in real-world patients.
A 20 años de ECLIPSE, repasamos el estudio que transformó la comprensión de la EPOC, revelando su heterogeneidad, progresión y biomarcadores clave.
Review of the treatable traits approach in bronchiectasis, exploring phenotypes, endotypes, comorbidities, and its translation into clinical practice.
Study reveals systemic immune alterations in bronchiectasis patients with chronic Pseudomonas infection, highlighting persistent immune imbalance.
Video de la presentación «Novedades GOLD 2026», en el que se trataron, entre otros aspectos: cambios en diagnóstico de la EPOC, tratamiento, comparativa con GESEPOC, etc.
This follow-up cohort study explores cardiac remodeling and reduced exercise tolerance in adolescents born small for gestational age, highlighting long-term cardiovascular implications.
Discover how personalized COPD care integrates phenotypes, endotypes, GETomics, trajectome, syndemics, and treatable traits to improve patient outcomes.